MDMA THERAPY

In many discussions about psychedelics and depression, the same picture emerges: the substance is seen as primarily an “aid” that makes psychotherapy more powerful. That idea is understandable, especially since many modern studies work with the model of psychedelic-assisted psychotherapy. At the same time, scientifically, it is likely too one-sided. After all, there is increasing evidence that some psychedelics can also have an antidepressant effect themselves, as a pharmacological intervention. This does not mean that therapy is unimportant, but it does mean that it is worthwhile to look at the story from a broader perspective.

In this article, we explore why the emphasis often lies on therapy, which data point to a direct pharmacological effect, and what that means for safety, prognosis, and harm reduction. In doing so, we explicitly distinguish between research findings, hypotheses, and what remains primarily interpretation.

Why psychedelics are often seen as 'therapy enhancers'

The modern “psychedelics renaissance” has been strongly shaped by the world of psychiatry, psychology, and psychotherapy. This is reflected in research teams, academic terminology, and treatment protocols. It is therefore logical that results are often explained within a therapeutic framework: preparation, session guidance, and integration are seen as core components.

In addition, there is a methodological point. Psychedelics produce noticeable effects, making blinding in trials difficult. Participants often guess whether they received the active substance or a placebo, and expectations can influence outcomes. Researchers also frequently mention “allegiance bias”: the likelihood that researchers or centers, consciously or unconsciously, already have a preference for a particular therapeutic model. This makes it harder to clearly distinguish what is primarily due to pharmacology and what is due to context, guidance, and meaning-making.

This does not mean that the interpretation of therapy is “wrong.” Rather, it means that the strong focus on therapy can give a structural color to how the field views effectiveness.

The pharmacological antidepressant effect: what exactly do we mean?

By a pharmacological effect, we mean that the agent itself causes measurable changes associated with a reduction in depressive symptoms, independent of an extensive psychotherapy program as an active treatment component. In practice, this separation is never perfect, because even a minimalist research setting still contains context: a safe space, prior explanation, monitoring, and human support.

However, it is certainly possible to design studies in which formal psychotherapy is limited as much as possible. If strong effects are still observed, that is an indication that the substance itself can make a substantial contribution.

Research signals: short-acting agents as a “test case”

One of the most discussed lines in the recent debate comes from studies with very short-acting substances such as (5-MeO-)DMT. Precisely because the acute experience is relatively brief, a psychotherapy script lasting for hours is less inevitable than with, for example, LSD or psilocybin. This makes these substances interesting if you want to understand how much of the effect might be pharmacological.

Some modern studies have attempted to minimize psychotherapy during the trial or limit changes to ongoing therapy. If rapid declines in depression scores and clear differences compared to placebo are nevertheless found, this is difficult to reconcile with the claim that “therapy alone” does the work. At the same time, caution remains necessary: sample sizes are not always large, blinding remains complex, and follow-up is often limited.

Ayahuasca research is also cited in this context. Ayahuasca is often associated with ceremony and ritual, leading people to quickly assume that context is the primary explanation. However, there are also placebo-controlled research designs with a relatively austere setting: explanation, a controlled environment, and support if needed, but no extensive multi-day psychotherapy protocol. The fact that such studies nevertheless report rapid effects at least supports the possibility that the substance is more than just a “therapeutic catalyst”.

A more extensive discussion of this perspective and the debate on therapy versus pharmacology can be found in the source text at Trip forum. This is an opinion forum article that discusses and interprets research; therefore, it is not a clinical guideline, but it can help to clarify the underlying questions.

Biological plausibility: BDNF, neuroplasticity and inflammation (with uncertainties)

Why do researchers think that psychedelics can have a direct antidepressant effect at all? An important answer is biological plausibility. Reviews and experimental research regularly point to pathways related to neuroplasticity, including the BDNF system (brain-derived neurotrophic factor). BDNF is involved in processes associated with the adaptability of neural networks.

Some studies report changes in biomarkers that support the idea that there is not only a “meaningful experience,” but also measurable biological effects. At the same time, it remains important to remain realistic: biomarker findings rarely translate directly to clinical outcomes, and different studies use different measurement points and methods. It is therefore an indication, not conclusive proof.

In addition, there is growing interest in possible effects on neuroinflammation. In some people, inflammation may play a role in depressive symptoms. Preclinical and mechanistic literature describes pathways through which serotonergic psychedelics could modulate inflammatory processes. However, here too, the step from mechanism to reliable clinical prediction is significant. It is a plausible hypothesis that needs to be further confirmed in well-designed research.

Therapy remains relevant, but possibly not the only driver

The fact that psychedelics can contribute pharmacologically does not render psychotherapy superfluous. Many people benefit from preparation (intentions, managing anxiety, expectations), support during the experience (safety, co-regulation), and integration afterward (giving meaning, behavioral change, dealing with what has been released). Guidance can also help recognize risky patterns, such as pursuing repeated sessions without integration, or using psychedelics as an escape.

However, if part of the antidepressant effect is pharmacological, this may indeed raise the question of whether the field sometimes assumes too quickly that “more therapy” is always the explanation for better outcomes. In some datasets, more therapeutic time appears to be associated with stronger improvements, but due to bias and expectations, it is difficult to derive hard causality from this.

Safety and harm reduction: what does this mean in practice?

The pharmacological perspective can unintentionally pose a risk: if people think “it is primarily a substance effect,” they may underestimate guidance and preparation. Yet set and setting, physical safety, risk screening, and aftercare can be crucial, regardless of the precise relationship between pharmacology and therapy.

It is important to remain clear: MDMA sessions can currently only be discussed within scientific research or in clinical practice via harm reduction. In practice, this means focusing on risk reduction, proper preparation, realistic expectations, and recognizing contraindications and warning signs. This article provides general information and is not individual medical advice.

Anyone considering a session would generally do well not only to look at “does it work,” but also at questions such as: how is safety ensured, how is the guidance organized, what happens during difficult experiences, and what does integration look like. On mdmatherapie.nl, you will find more context regarding the topic of therapy in relation to MDMA on the page. MDMA therapy.

Conclusion

From a scientific perspective, the question of whether psychedelics are “more than an aid in therapy” is justified. Evidence is accumulating that some psychedelics, under certain circumstances, can make a direct pharmacological antidepressant contribution. At the same time, the field is methodologically complex: blinding, expectations, and biases in research can color conclusions, and biomarker narratives remain partly provisional.

The most balanced position is therefore: therapy and guidance can be important for safety and integration, but it is not inherently fair to attribute all effects primarily to psychotherapy. Those wishing to explore an MDMA session further from a harm-reduction perspective can, if desired, visit the sign-up page for an MDMA session.